Is somatropin FDA-approved, and what does the research show?

What is somatropin?

Somatropin is human growth hormone made by recombinant DNA technology in bacteria, with the same 191-amino-acid sequence as the hormone your pituitary gland makes ¹. It is the active ingredient in the growth hormone products sold under brand names such as Genotropin, Humatrope, Norditropin and Omnitrope ². In children it drives growth in height; in adults it acts on body composition, on glucose output from the liver and on the breakdown of fat ¹. People often call it HGH, and federal law defines "human growth hormone" as "somatrem, somatropin, or an analogue of either of them" ⁴.

Is somatropin FDA-approved?

Yes. Somatropin is approved by FDA as a prescription medicine ¹. The Norditropin label approves it for children with growth failure from inadequate growth hormone secretion ¹. It also covers short stature with Noonan syndrome, Turner syndrome or idiopathic short stature, children born small for gestational age without catch-up growth, and growth failure from Prader-Willi syndrome ¹. In adults it is approved for "the replacement of endogenous GH in adults with growth hormone deficiency" ¹.

Other brands' labels add uses of their own: Humatrope for short stature in SHOX deficiency, a gene disorder, and Serostim for adults with HIV and wasting or cachexia ³, ⁵. FDA's Drugs@FDA lists twelve approved somatropin applications, ten of them with a product still listed for prescription as of its data of November 6, 2026 ².

Their original approvals run from Humatrope on October 16, 1986, to Accretropin on January 23, 2008 ². Between them come Nutropin, Genotropin, Zomacton, Nutropin AQ, Saizen, Serostim, Norditropin, Zorbtive and Omnitrope ². The current Humatrope, Norditropin and Serostim labels each carry "Initial U.S. Approval: 1987" ¹, ³, ⁵. The two records disagree by a year, and no source on this page reconciles them ², ¹.

Some brands are leaving the market. Genentech said it would discontinue all Nutropin AQ NuSpin formulations in the United States on December 31, 2024, for business reasons unrelated to safety or quality ⁶. Lilly says it is permanently discontinuing distribution of Humatrope on December 31, 2026, with limited product available until supply runs out ⁷. Drugs@FDA still listed both with marketing status "Prescription" as of its data of November 6, 2026 ². Whether stock remains is not something Drugs@FDA shows ².

Federal law has a subsection written for this hormone alone, 21 U.S.C. § 333(e), headed "Prohibited distribution of human growth hormone" ⁴. Under 21 U.S.C. § 333(e), "whoever knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary of Health and Human Services under section 355 of this title and pursuant to the order of a physician, is guilty of an offense punishable by not more than 5 years in prison, such fines as are authorized by title 18, or both" ⁴. The penalty rises to ten years where the offense involves a person under 18 ⁴.

For a reader, the route to somatropin is a physician's prescription for a condition the label names, dispensed as the approved product ¹, ⁴. The Norditropin label says it "is not indicated for the treatment of non-GH deficient adults" ¹. Anti-aging, body composition in healthy adults and athletic performance are not among the approved uses ¹, ⁴.

See the FDA status of every peptide, updated weekly.

How does somatropin work?

Somatropin binds to growth hormone receptors on the surface of target cells, which switches on the production of growth hormone-dependent proteins, including IGF-1 ¹. IGF-1, insulin-like growth factor 1, carries part of the hormone's effect to the tissues; the rest is direct ¹. In children with growth hormone deficiency it acts on the growth plates of the long bones and raises the rate of growth in height in most treated children ¹. Its metabolic effects include higher glucose output from the liver, more protein synthesis and lipolysis, the breakdown of stored fat ¹.

In 26 healthy adults whose own growth hormone was suppressed, a single injection raised IGF-1 from a mean of 190 to 276 ng/mL at about 24 hours ¹. By 96 hours the level was back to baseline ¹. These are the label's descriptions of an approved drug, so the tier is "approved by FDA," not a proposed mechanism ¹.

What does the research show?

The evidence behind the approval is summarized on the label, from randomized trials in children and adults ¹. Studied in children with growth hormone deficiency: a randomized, open-label trial of 111 children compared three dose levels over two years ¹. Mean height gain over the two years ranged from 17.6 cm in the lowest-dose group to 23.7 cm in the highest ¹.

Studied in girls with Turner syndrome: a randomized trial of 68 girls treated them for a mean of 8.4 years ¹. The 46 who reached final height averaged 161 cm, and 70 percent of them finished within the normal range ¹. Studied in children born small for gestational age: a randomized, double-blind trial of 53 Dutch children without growth hormone deficiency ran to final height, up to 13 years ¹. Thirty-eight reached final height, and 24 of those 38 were within the normal range of their peers ¹.

Studied in children with Noonan syndrome: 21 children were randomized and treated to final height, with 6 more following the protocol ¹. Final height, collected later from 24 of them, was 1.5 to 1.6 standard deviation scores above baseline, which the label puts at 9.1 to 11.5 cm at age 18 ¹.

For idiopathic short stature and Prader-Willi syndrome, the Norditropin label relies on trials of another somatropin product ¹. In the idiopathic short stature trial, 105 children, identified afterward as having it and prepubertal at randomization, were randomized to treatment or observation and followed to final height ¹. Treated girls gained a mean 9.8 cm and treated boys 5.0 cm over untreated controls ¹. In the two Prader-Willi trials, small ones of 27 and 16 children, treated children grew 11.6 and 10.7 cm in the first year against 5.0 and 4.3 cm untreated ¹.

Studied in adults with growth hormone deficiency: six randomized, double-blind, placebo-controlled trials were performed, and the label describes two ¹. In 31 adults with adult-onset deficiency treated for six months, lean body mass rose 1.12 kg on somatropin and fell 0.63 kg on placebo ¹. The difference was 1.74 kg, with a 95 percent confidence interval of 0.65 to 2.83 ¹. Body fat fell 2.83 percentage points against a rise of 1.92 on placebo, a difference of 4.74 points ¹.

In 49 men with childhood-onset deficiency, the pooled treatment groups gained 1.40 kg more lean mass than placebo and lost 4.24 points more body fat ¹. These trials measured body composition over six months; the label reports no outcome beyond that horizon in adults ¹.

What the label does not show: it says Norditropin "is not indicated for the treatment of non-GH deficient adults" ¹. Its only treatment-outcome data in such adults come from two intensive-care trials in which more patients died on somatropin ¹. No published trial of somatropin for athletic performance was found among this page's sources as of November 9, 2026. Healthy older adults, the group anti-aging use targets, were studied in small trials elsewhere.

In 1990, a trial of 21 healthy men aged 61 to 81 with low IGF-1 gave 12 of them growth hormone for six months and left 9 untreated ⁸. In the 12 treated men, lean body mass rose 8.8 percent, fat mass fell 14.4 percent and lumbar spine bone density rose 1.6 percent ⁸.

A 2007 systematic review of randomized trials in healthy older people covered 18 study populations, in which 220 participants received growth hormone for a mean of 27 weeks ⁹. Fat mass fell 2.1 kg and lean mass rose 2.1 kg, weight did not change, and bone density and most blood lipids did not change ⁹. Treated participants were more likely to have soft tissue swelling, joint pain, carpal tunnel syndrome and, in men, breast enlargement ⁹. They were somewhat more likely to develop diabetes or impaired fasting glucose ⁹. The authors concluded that growth hormone "cannot be recommended as an antiaging therapy" ⁹.

What are the side effects?

In adults with adult-onset growth hormone deficiency, the label's six-month placebo-controlled trial compared 53 patients on Norditropin with 52 on placebo ¹. Peripheral edema, swelling of the limbs, occurred in 42 percent against 8 percent on placebo, and edema in 25 percent against none ¹. Leg edema was reported in 15 percent against 4, joint pain in 19 against 15, and muscle pain in 15 against 8 ¹. Tingling or numbness occurred in 11 percent against 6 ¹. Abnormal glucose tolerance was reported in 6 percent against 2, and type 2 diabetes in 5 percent against none ¹.

In the trial of children with growth hormone deficiency, the most frequent reactions were headache, sore throat, middle ear infection and fever ¹. In the Noonan syndrome study, scoliosis was reported in 5 of the 24 children followed, and in the first Turner study two girls had a serious worsening of preexisting scoliosis ¹. Six of 53 children born small for gestational age had raised fasting glucose after a year of treatment ¹.

The label's first warning is increased mortality in acute critical illness ¹. In two placebo-controlled trials of 522 critically ill adults without growth hormone deficiency, 42 percent died on pharmacologic amounts of somatropin against 19 percent on placebo ¹. The others include sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems ¹. Neoplasms are a further warning: the risk of an existing tumor progressing, and of second tumors in childhood cancer survivors treated with radiation to the brain or head ¹.

The label also warns of glucose intolerance and new type 2 diabetes, intracranial hypertension, serious allergic reactions, fluid retention, low cortisol and hypothyroidism ¹. In children it adds slipped capital femoral epiphysis and worsening scoliosis; in all patients, pancreatitis and loss of fat tissue at injection sites ¹. Postmarketing reports include leukemia "in a small number of GH deficient children" treated with growth hormone products ¹. Long-term overdose "could result in signs and symptoms of gigantism and/or acromegaly" ¹.

The label's contraindications begin with acute critical illness after open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure ¹. Next are children with Prader-Willi syndrome who are severely obese or have upper airway obstruction, sleep apnea or severe respiratory impairment ¹. The rest are active malignancy, hypersensitivity to the product, active proliferative or severe non-proliferative diabetic retinopathy, and children with closed epiphyses ¹.

In sport

Growth hormone is prohibited at all times, in and out of competition, under section S2.2.3 of WADA's 2026 Prohibited List, "Growth hormone (GH), its analogues and fragments" ¹⁰. WADA, the World Anti-Doping Agency, places it in class S2, peptide hormones, growth factors, related substances and mimetics, whose substances are all non-specified ¹⁰. Somatropin is recombinant human growth hormone with the hormone's own sequence, so the entry names the substance itself, not only its analogues ¹, ¹⁰.

What JumpstartMD offers

JumpstartMD does not prescribe somatropin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026. Our guide Sermorelin vs HGH compares the two.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.